| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d0d51806567d8f1e090d1507c5f6dd3a |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4816
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4808
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-485
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0073
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1611
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1617 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 |
| filingDate |
2014-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2015-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e098fc599f7fa2242cc1ff3d18498756
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e1b2b12c8f95c91fd2a9ce7502ef0ca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_03c5f3c5f8dc1a6903db44eade6e388d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_efd8b588b80c60aa631c09bf5270e844
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb25fd371d36152fa9c872c4938c0d41 |
| publicationDate |
2015-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8945612-B2 |
| titleOfInvention |
Capsules containing high doses of levodopa for pulmonary use |
| abstract |
The present invention provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L. The invention further provides a capsule containing an inhalable powder composition wherein the composition comprises about 75% by weight or more levodopa, dipalmitoylphosphatidylcholine (DPPC) and a salt characterized by a working density of less than about 100 g/L wherein the capsule material comprises hydroxypropylmethylcellulose (HPMC) and titanium dioxide. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9642812-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9539211-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018036253-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10238607-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015342890-A1 |
| priorityDate |
2012-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |